The Medical Advisor

Executive Summary Dr. Thomas N. Seyfried , Professor of Biology at Boston College, proposes a metabolic model of cancer that challenges the dominant genetic explanation and conventional oncology treatments. Rather than viewing cancer as primarily driven by gene mutations, Seyfried asserts it is fundamentally a metabolic disease centered on dysfunctional cellular energy production. This reframing draws on and expands the historical Warburg effect , emphasizing how cancer cells rely on fermentative metabolism of glucose and glutamine due to defective mitochondrial function.  A 2026 large-scale population study published in Nature Communications demonstrated that machine learning-predicted insulin resistance was associated with increased risk of 12 cancer types in nearly 500,000 individuals from the UK Biobank. This finding strengthens a growing thesis: Metabolic dysfunction is not merely a comorbidity — it may be a central modifiable axis in oncogenesis. Standard of Care: T...